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ABSTRACT: Introduction: New antiretroviral therapy (ART) 
regimens for HIV could improve clinical outcomes for patients 
and to change the natural history of the infection. National 
and international guidelines currently recommend starting the 
treatment of infected individuals to prevent the deterioration 
of the immune system and to control viral replication, and 
prevention of the transmission of HIV infection. Objectives: 
to analyze the use of antiretroviral therapy those include 
Atazanavir/ritonavir (ATV/r) or Efavirenz (EFV) in the first line 
of treatment for adult patients living with HIV. Material and 
Methods: a retrospective cohort study between August 2019 to 
July 2020 and focused on the Clinical Immunology Service/day 
Hospital of the Instituto de Medicina Integral Prof. Fernando 
Figueira – IMIP. The data were taken from the records 
selected at random and recorded in standardized questionnaires 
with subsequent transcription in computerized spreadsheets. 
The project was approved by the Human Research Ethics 
Committee (CEP) of IMIP/PE. The data were transcribed in the 
Excel program, analyzed on Epi Info™. Results: 131 patients 
participated in the study using EFV or ATV/r as the third drug 
in the antiretroviral regimen, 73.3% of whom were EFV patients 
and 26.7% using ATV/r. Initial viral suppression was observed 
in 88% (p > 0.05) of patients, regardless of the regimen used. 
Schemes containing ATV/r showed a prevalence of 47.1% of 
adverse effects and EFV 52.1% (p < 0.001). Conclusion: The 
findings of this study suggest that both ATV/r and EFZ showed 
similar effectiveness when used as a first line of treatment.
Keywords: Antiretroviral Therapy Highly Active; Effectiveness; 
Safety; Efavirenz; Atazanavir; HIV.
RESUMO: Introdução: Novos regimes de terapia antirretroviral 
(TARV) para HIV podem melhorar os resultados clínicos para 
os pacientes e de alterar a história natural da infecção. Os 
guidelines nacionais e internacionais recomendam atualmente 
a iniciar o tratamento dos indivíduos infectados para prevenir 
a deterioração do sistema imunológico e controlar a replicação 
viral, e consequente prevenção da transmissão da infecção pelo 
HIV. Objetivo: Analisar o uso da terapia antirretroviral que 
incluem Atazanavir/ritonavir (ATV/r) ou Efavirenz (EFV) na 
primeira linha de tratamento de pacientes adultos vivendo com 
HIV. Material e Métodos: O presente trabalho consiste em um 
estudo coorte retrospectivo. A coleta de dados ocorreu no período 
de agosto de 2019 a julho de 2020 e se concentrou no Serviço 
de Imunologia Clínica/Hospital-Dia do Instituto de Medicina 
Integral Prof. Fernando Figueira - IMIP. Os dados foram retirados 
dos prontuários selecionados de maneira aleatória e registrados 
em questionários padronizados com posterior transcrição em 
planilhas computadorizadas. O projeto foi aprovado pelo Comitê 
de Ética em Pesquisa em Seres Humanos (CEP) do IMIP/PE. 
Os dados foram transcritos no programa Excel, analisados no 
Epi Info™. Resultados: 131 pacientes participaram do estudo 
utilizando EFV ou ATV/r como terceira droga do esquema 
antirretroviral, sendo 73,3% pacientes EFV e 26,7% usando 
ATV/r. A supressão viral inicial foi observada em 88% (p > 
0,05) dos pacientes, independentemente do esquema utilizado. 
Esquemas contendo ATV/r apresentaram uma prevalência de 
47,1% de efeitos adversos e EFV 52,1% (p < 0,001). Conclusão: 
Os achados do desse estudo sugerem que tanto ATV/r quanto 
o EFV apresentaram efetividade semelhante quando utilizados 
como primeira linha de tratamento.
 
Palavras-chave: Terapia antirretroviral de alta atividade; 
Efetividade; Segurança; Efavirenz; Atazanavir; HIV.
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INTRODUCTION
Since the advent of antiretroviral therapy (ART), several studies have demonstrated over time the 
benefit of starting treatment earlier and earlier, altering the 
natural history of the infection, preventing the deterioration 
of the immune system and controlling replication, and 
consequent prevention of transmission of HIV infection1. 
Actually, the main treatment guides in the world, including 
the Brazilian, indicate ART at the time of HIV infection 
diagnosis, regardless of CD4+ T cell count, viral load and 
presence of symptoms2. However, barriers to access to ART 
patients living with HIV (PLHIV) exist with important 
differences between countries, especially according to 
socioeconomic levels and models of organization of health 
systems3-7.
For naive patients on antiretroviral treatment, the 
Brazilian guide8-10, actually recommends starting ART 
schemes using two Nucleotide analog reverse-transcriptase 
inhibitors (NRTIs), with the Ministry of Health and World 
Health Organization (WHO) recommending Lamivudine 
(3TC) and Tenofovir (TDF), associated with an Integrase 
Inhibitor (INIs), Dolutegravir (DTG)9,10.
Antiretroviral regimen composed of two NRTIs and 
a protease inhibitor (PI) - atazanavir - boosted with ritonavir 
(ATV/r) demonstrated excellent efficacy in controlling viral 
replication, good durability in treatment naive patients and 
a high genetic barrier to resistance and it has relatively few 
metabolic adverse effects9. ATV/r has better gastrointestinal 
tolerance and less impact on glycolipid metabolism, in 
addition to being the only PI not associated with increased 
cardiovascular risk. It also presents the best dosage, as 
the use of a single daily dose, enables better treatment 
adherence11,12.
The main adverse effects of ATV/r are reversible 
indirect hyperbilirubinemia, with or without jaundice, 
but without the concomitant hepatic elevations of 
transaminases, nephrolithiasis, nephrotoxicity and 
cholelithiasis12-16. It is worth noting that ATV requires acidic 
gastric pH for dissolution17.
Efavirenz (EFV), a non-analogous nucleoside 
reverse transcriptase inhibitor (NRTI), may be a great 
choice for some patients, although this drug has a low 
genetic barrier, facilitating the development of resistance9. 
EFV has a long history of widespread use globally, and 
its minimal interaction with rifampicin has become an 
option for patients who need concomitant treatment for 
tuberculosis (TB)9. It is worth noting that EFV can cause 
central nervous system (CNS) side effects such as abnormal 
dreams, dizziness, pain headache and depression, which 
resolve over a period of days to weeks in most patients; 
elevation of LDL cholesterol and triglycerides, in addition 
to a prolongation of the QT interval18,19.
Studies evaluating the effectiveness and safety of 
different antiretroviral regimens for the treatment of HIV 
infection can support the recommendations of current 
national and international protocols that are based on 
studies of effectiveness. Thus, the aim of the study was 
to analyze the use of antiretroviral therapy that include 
Atazanavir/ritonavir or Efavirenz in the first line of 
treatment for adult patients living with HIV.
MATERIALS AND METHODS
This is a retrospective cohort study of HIV-1 
patients using ART. The study covered data collected from 
medical records of patients seen at the Clinical Immunology 
Service/Day-Hospital at Institute of Integral Medicine 
Professor Fernando Figueira (IMIP), Brazil. 
Were eligible subjects diagnosed with HIV 
infection, of both sexes and aged above 18 years in the use 
of antiretroviral regimens containing ATV/r or EFV as first 
line treatment. In addition to these medications, depending 
on the individual regimen, everyone included in the study 
used Lamivudine and Tenofovir. These should be monitored 
by the Specialized Assistance Service/Day-Hospital (SAE/
DH) between April 1996 and October 2018, with 25 people 
who used Atazanavir/ritonavir and 61 who used Efavirenz 
started treatment before 2014. In addition, all participants 
in this study had at least one result of a plasma viral load 
test for HIV-1 RNA (CV RNA HIV-1) and LT CD4 + and 
six months of follow-up.
Were excluded, PLHIV who had started ART in 
other services, previous prophylactic use of ARVs, patients 
with coinfections with hepatitis B and C, HTLV, pregnant 
women, people with leprosy and defining neoplasms still 
under treatment, in addition to chronic and cardiac renal 
failure and liver, autoimmune diseases, dyslipidemia and 
use of corticosteroids, before the start of ART.
The patients’ medical records were obtained through 
random non-probabilistic sampling, on the premises of the 
SAE/DH medical file and, using the Microsoft Excel 2017 
program, random numbers were generated, establishing the 
order of verification.
Data were collected between March 2019 and 
December 2019, using information from clinical records, 
the computerized system of laboratory test reports and 
the System Laboratory Tests Control of the National 
Network of Lymphocyte Count CD4+/CD8+ and viral 
Load (SISCEL). Through SISCEL, it was possible to verify 
LT CD4+ and CV RNA HIV-1 counting exams until 2011 
and results of genotyping and ARV dispensing per patient 
from 2011.
Patients were followed for the entire period 
they used ARVs of interest for the study, the end of 
use being considered through the exchange report in 
the medical record with the dates confirmed by the 
information from SISCEL. The data were recorded 
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in a computerized spreadsheet, based on a previously 
standardized questionnaire containing sociodemographic 
information (date of birth, city of residence, ethnicity, sex, 
marital status, sexual orientation, education, occupation and 
income); behavioral and lifestyle habits (smoking, drinking, 
use of illicit drugs and being a sex worker); clinical and 
laboratory data (transmission, opportunistic infections, 
presence of chronic diseases prior to ART and initial 
clinical classification, according to the adapted Centers for 
Disease Control and Prevention [CDC] criteria)20,21 results 
of laboratory tests and genotyping); HAART used (time 
between diagnosis and start of HAART, time on HAART 
use, therapeutic regimen, adherence reported by the doctor 
in the medical record and confirmed by SICLOM records, 
adverse effects and therapeutic failures) and co-infections 
(hepatitis B and C, syphilis , HTLV, toxoplasmosis, 
cytomegalovirus and tuberculosis).
Therapeutic effectiveness was defined as maximum 
viral suppression six months after the start of treatment. 
The maximum limit of detection in viral load assays used 
during the study period varied between ≤ 400 copies/ml (up 
to 2004), ≤ 50 copies/ml (up to 2013) and ≤ 40 copies/ml 
(to the present day)19. Immune recovery (increased CD4+ 
LT levels) during follow-up was also assessed. The safety 
parameter for the use of ART included reporting in medical 
records of adverse effect, motivating or not the exchange 
of antiretroviral drugs.
This research was approved by the Human 
Research Ethics Committee of Institute of Integral 
Medicine Professor Fernando Figueira - IMIP (CAAE 
00172318.9.000.5201).
All analyzes were performed using the Epi Info 
version 7.0 for Windows statistical package. Descriptive 
statistics were used to present the data using mean and 
95% confidence interval (CI) (normal distribution) or 
median and interquartile range (IIQ, non-normal data) for 
numerical variables and relative frequency distribution for 
categorical variables. To compare antiretrovirals, Pearson’s 
chi-square test was used for categorical variables and for 
continuous variables, the Kruskal-Wallis test (non-normal 
data) followed by Dunn’s post-hoc test, the significance p 
value used was p < 0.05.
RESULTS
In the beginning, 396 adult HIV-1 patients who were 
being followed up at SAE/DH were eligible to participate in 
the study. However, 265 patients were excluded, according 
to the study’s eligibility criteria. In the end, 131 patients 
participated in the study using EFV or ATV/r as the third 
drug in the antiretroviral regimen, with 96 (73.3%) patients 
using EFV and 35 (26.7%) patients using ATV/r.
The demographic and social characteristics of the 
participants included in the survey are shown in Table 1. 
Considering the total number of participants, the median 
age was 39 years (IIQ = 33-44); 86.26% lived in the capital 
or metropolitan region of Recife (RMR), while 13.74% 
were from other cities in the state of Pernambuco; 54.96% 
were female, for whom the transmission of HIV-1 occurred 
through heterosexual sex, while in men the exposure 
category for HIV-1 infection in men who have sex with 
men (MSM), corresponded to 38,98% of men (p < 0.05).










Not white 100 81.97
Marital status
Married/stable union 68 66.02
Not married/widower/divorced 35 33.98
Scholarity
≤ 8 years 52 46.43
> 8 years 60 53.57
Occupation
Employee/Student 49 40.83%














Up to 1 minimum wage 45 54.22%
More than 1 minimum wage 38 45.78%
Subtitle: INSS - Instituto Nacional do Seguro Social (Brazil).
Source: Study data.
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As for the comorbidities reported before the start 
of ART, it can be observed that there was no difference 
between the groups (p > 0.05), with psychiatric disorder 
being registered in 4.58% (n=6) of the patients, 6.84% 
(n=8) alcoholism, 3.82% (n=5) with systemic arterial 
hypertension, 1.53% (n=2) with reports of illicit drug use, 
0.76% (n=1) diabetes type 2 melitus and 0.76% (n=1) some 
neoplastic disorder.
Before the start of treatment with the studied 
drugs, of AIDS-defining diseases, according to the 
CDC20, it was possible to identify in the Efavirenz group a 
neurotoxoplasmosis with a presentation of 7.2% and among 
users of Atazanavir esophageal candidiasis with 5,9%. 
However, when the Rio de Janeiro Caracas criterion was 
observed21, the most reported symptom was anemia and/
or lymphopenia, affecting 55.1% of patients.
When observing the average number of days 
between the diagnosis of HIV and the beginning of ART, 
a great difference was observed for the beginning of the 
antiretroviral regimen after its indication. Individuals who 
used EFV started treatment earlier, with an average of 
119 (IIQ = 30-705) days, with a difference of 121 days in 
relation to those who used ATV r (p > 0.275), who started 
treatment only after an average of 240 (IIQ = 83-1191) 
days from the date of diagnosis (Table 2).
However, no difference can be identified in the time 
of use of both Efavirenz and Atazanavir/ritonavir, since in 
both situations the use was observed for 204 weeks, with 
IIQ = 98-293 for ATV/r and IIQ 118-363 for EFV.
As for the laboratory characteristics of patients 
before starting ART (Table 2), the ATV/r group had a higher 
CD4+ LT count compared to the initial EFV count (p = 
0.038). However, it is noteworthy that 59.3% of patients 
had CD4+ LT levels below 350 cells/mm³ in both groups.
There were also no differences in the values of CV 
RNA HIV-1 at the beginning of treatment for the ARVs 
involved in this study (p = 0,06), either in the number of 
copies of HIV RNA or in the base 10 logarithm (log 10).
There was a reduction in CV RNA HIV-1 and an 
increase in LT CD4+, when comparing the pre-treatment 
period and the last examination recorded in the medical 
record (p < 0.05). There was no significant difference in 
CV RNA HIV-1 of patients using ATV/r when compared 
to the median values achieved by patients using EFV (p < 
0.05) in the last exam.
Initial viral suppression was observed in 88% of 
patients, regardless of the scheme used, with no difference 
between groups (p > 0.05). The median time between the 
start of ART and the first test showing viral suppression 
was 184 days for the ATV/r group and 147 days for EFV.
Table 2. Characteristics related to antiretroviral therapy, clinical and laboratory of patients before the start of treatment and in the last 
laboratory examination performed using antiretroviral. Recife-PE, Brazil, 2020
Variables Total ATV/r (n=35) EFV (n=96) pa
Time between diagnosis and initiation of 
antiretroviral therapy (days), median and (IIQ) 179.5 240 (83-1191) 119 (30-705) 0.275
Antiretroviral use time (days), median 1467 1505 1429 0.548
T CD4+ lymphocytes (cells/mm³), median 0.,038
Pre-treatment 335 380 291
Last exam 657 701 614
T CD4+ lymphocytes (%), median 0.291
Pre-treatment 18 19 17
Last exam 30 30 31
Plasma viral load of HIV-1 RNA
Pre-treatment (copies/ml), median 30090 15760 44421 0.06
Last exam, (n), % de undetectable 209 (79.1) 674 4302 0.870
Viral suppression (%)
Yes 110 (88) 28 (84.4) 82 (88.2)
No 15 (12) 4 (12.5) 11 (11.8)
Time to deletion (days), median 155 184 147 0.103
Subtitle: ATV/r, atazanavir enhanced with ritonavir; EVF, Efavirenz;
aTeste Kruskal Wallis H seguido do post-hoc de Dunn
Source: Study data.
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 Considering the combination of viral suppression 
and absence of adverse effects, ATV/r was superior (p < 
0.001), with 50.0% of patients without such events, while 
EFV, in which there was therapeutic effectiveness and no 
effect adverse in 42.7% of patients. Schemes containing 
ATV/r showed a prevalence of 47.1% of adverse effects 
and EFV 52.1%. It appears that the most prevalent adverse 
reactions for the scheme containing ATV/r were jaundice 
(17.6%), nausea and dyslipidemia (both with n=4; 11.5%), 
while for EFV, dizziness (13.5%) and insomnia (12.5%) 
were the most frequently reported (Table 3).
Table 3. Prevalence of adverse effects. Recife-PE, Brazil, 2020
Adverse effects ATV/r (n=34) EFV (n=96)n (%) n (%)
Diarrhea 2 (5.9) 2 (2.1)
Headache 1 (2.9) 8 (8.3)
Dizziness 1 (2.9) 13 (13.5)
Depression - 8 (8.3)
Nightmares - 6 (6.3)
Elevation of triglycerides - 3 (3.1)
Skin rash 1 (2.9) 5 (5.2)
Insomnia - 12 (12.5)
Anemia 2 (5.9) -
Emotional lability 1 (2.9) 12 (12.5)
Asthenia - 2 (2.1)
Suicidal thinking - 2 (2.1)
Nausea 4 (11.8) 6 (6.3)
Lipodystrophy 1 (2.9) 5 (5.2)
Jaundice 6 (17.6) -
Glucose intolerance 1 (2.9) 1 (1.0)
Dyslipidemia 4 (11.8) 7 (7.3)
Vomiting 2 (5.9) 3 (3.1)




The results of this study show that most people 
seen at the Day-Hospital/IMIP are women, on average, 
39 years old, which differs from the data published 
in the latest epidemiological bulletin released by the 
Ministry of Health22. In this, it is observed the Brazilian 
population living with HIV is made up mostly of men 
aged between 20 and 34 years. The epidemiological 
bulletin of the Government of the State of Pernambuco 
found that heterosexual transmission was responsible 
for HIV infection among women in the state23. However, 
among men, the most common route of transmission was 
homosexual. Data which corroborate with the present study.
In a randomized, multicentre controlled clinical 
trial with 103 patients, there was a 63% viral suppression 
of ATV/r in triple therapy, which demonstrated in the long 
term that the effectiveness of monotherapy with ATV/r was 
lower when compared to triple therapy containing ATV/
r24. This finding differed from the result of the present 
study, in which viral suppression occurred regardless of 
the ART used, with viral suppression observed in 184 days 
for the ATV/r group. As well as, the clinical trial showed a 
divergent result, with regard to the occurrence of adverse 
effects, considering the occurrence in 8% of patients in the 
monotherapy arm and 4% in triple therapy (p = 0.436)24. 
However, in a retrospective cohort, a significant increase in 
total bilirubin was demonstrated among patients using ATV/
r25, being compatible with the results found in this study.
A phase IV clinical trial with 40 treatment naive 
patients showed a significant reduction in the viral load 
of the scheme containing EFV, and the effectiveness of 
ART would be 77.4%. In addition, there was a significant 
increase in the mean CD4+ LT count26. This trial showed 
a similar result with regard to viral suppression, taking 
into account the similarity of the results presented. In 
patients using EFV, dizziness (13.5%), insomnia (12.5%) 
and emotional lability (12.5%) were the most reported, 
equivalent data from the literature26. In systematic review 
and meta-analysis of network, which included 34.032 
patients, showed that efavirenz was the best-connected 
treatment with the other Integrase Chain Transfer 
Inhibitors. In addition, in this meta-analysis, dolutegravir 
and raltegravir showed superior efficacy and tolerance to 
efavirenz regimens27. The importance of these data is due 
to the fact that the toxicity profile, as well as the occurrence 
of adverse effects of ART, may be related to the increase 
in the morbidity and mortality of PLHIV, as well as the 
increase in costs of health services28.
Significantly, greater declines in HIV RNA and 
maximum control with these ARTs were evidenced, along 
with significantly greater increases in CD4+ T cells with 
up to 43 weeks of therapy. Despite a significantly greater 
increase in total bilirubin among patients using ATV/r, 
no other significant increase in adverse laboratory values 
between the two drugs. These data are compared to those 
found in a clinical trial that has been shown to be effective 
and safe in the treatment of HIV infection in treatment naive 
patients. However, there was a significant increase, but in 
normal ranges of total cholesterol, LDLc and glycemia; 
in addition, a significant increase in HDLc concentrations 
was observed. On the other hand, the concentrations of 
triglycerides, phosphates, calcium and waist measurements 
did not show significant changes26.
This study has limitations related to the lack of 
complete records of information in the clinical record, 
minimized by checking the data with the available 
computerized systems. Furthermore, the difference between 
the numbers of individuals in each group, especially for the 
ATV/r group, may have hindered the comparative analysis 
between the other ARV.
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CONCLUSION
It was possible to show that ATV / r and EFZ 
showed similar effectiveness when used as the first line 
of treatment. Adherence to treatment has been shown to 
be an independent protective factor for achieving viral 
suppression. In addition, the current study could benefit 
future patients who are indicated to start antiretroviral 
therapy as a treatment for HIV infection.
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